Nexo Therapeutics

Executive Summary

Nexo Therapeutics is a private, preclinical-stage biotechnology company headquartered in Cambridge, MA, dedicated to developing novel small molecule therapies against historically undruggable cancer drivers. Founded in 2021, the company leverages a proprietary chemical proteomics platform to systematically identify and validate high-value targets and generate selective drug candidates. With a mission to address significant unmet needs in oncology, Nexo aims to create transformative treatments for patients with limited options. The company has raised $60 million to date, underscoring investor confidence in its platform and approach. Nexo is advancing a pipeline of small molecule programs targeting key oncogenic drivers. While all programs remain in preclinical development, the company is progressing toward lead optimization and IND-enabling studies. Key near-term milestones include the selection of a clinical candidate and the presentation of in vivo efficacy data at major scientific conferences. With its innovative platform and experienced leadership, Nexo Therapeutics is well-positioned to deliver first-in-class therapies to patients and generate significant value for stakeholders.

Upcoming Catalysts (preview)

• Q2 2026Presentation of preclinical data for lead program at AACR 202670% success
• Q4 2026Announcement of clinical candidate nomination for first-in-class program60% success
• H2 2026Strategic partnership or collaboration leveraging chemical proteomics platform40% success